Merrick R. Almond, Ph.D. is a Senior Patent Agent in Knowles Intellectual Property Strategies, LLC. Dr. Almond’s practice focuses on chemical, pharmaceutical and biotechnology IP issues relating to U.S. and international patent preparation, prosecution, and due diligence investigations.
Dr. Almond has over twenty five years of industrial experience in the pharmaceutical and biotechnology industries and a track record of successful antiviral drug development. Dr. Almond began his career at Burroughs Wellcome Co. as a Senior Research Scientist where he led drug discovery programs targeted toward potential antiviral, anticancer and cardiovascular agents. He received the Wellcome Synthetic Organic Achievement Prize in1995 for his efforts in the antiviral field. Dr. Almond advanced to the position of Research Investigator at GlaxoWellcome Inc. where he led a HIV protease program.
In 1996, Dr. Almond joined Triangle Pharmaceuticals, Inc. as the Group Leader of Chemistry and subsequently advanced to the Director of Chemistry. While at Triangle Pharmaceuticals, Inc., Dr. Almond’s group invented novel synthetic processes for five development candidates. He chaired the Triangle Patent Committee and worked with outside counsel to develop and implement the IP strategy for the company. Dr. Almond was a key member of the Triangle strategic alliance team in the licensure of four Triangle products to Abbott Laboratories. Triangle Pharmaceuticals, Inc. was ultimately acquired by Gilead Sciences, Inc. in 2003 for $454 million.
In 2002, Dr. Almond joined Chimerix, Inc. as the Vice President of Medicinal Chemistry. While at Chimerix, Inc., Dr. Almond led and implemented the intellectual property strategy for the company. In addition, he was heavily involved in business development licensing and due diligence matters pertaining to CMX001 and CMX157. CMX157 was licensed to Merck in 2012 and CMX001 is currently in Phase III. Chimerix, Inc. went public in 2013 and has a market cap of $523 million (February 2014).
Dr. Almond has authored/co-authored twenty five publications in peer-reviewed journals and is the inventor/co-inventor on fourteen U.S. patents.
Dr. Almond received a Bachelor of Science Degree in Biochemistry from the College of Environmental Science and Forestry and a Ph.D. from Purdue University in Medicinal Chemistry. Dr. Almond’s Ph.D. thesis focused on the synthesis, hydrolysis and pharmacological utility of germinal aminoamides, a class of peptidomimetics. Dr. Almond held a postdoctoral appointment in research at Duke University where he worked with Dr. Bertram O. Fraser-Reid on the total synthesis of Avermectin A2a.
Prior to joining Knowles Intellectual Property Strategies, LLC, Dr. Almond was a patent agent with Myers, Bigel, Sibley and Sajovec, P.A. in Raleigh, North Carolina.
Dr. Almond is admitted to practice in the United States Patent and Trademark Office (USPTO).